GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Isis Pharmaceuticals, Inc. (ISIS) [hlAlert]

Rating:
Buy ISIS
up 264.89 %

Isis Pharmaceuticals, Inc. (ISIS) rated Buy with price target $18 by Morgan Joseph

Posted on: Friday,  Jan 9, 2009  8:25 AM ET by Morgan Joseph

Morgan Joseph rated Buy Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) on 01/09/2009, when the stock price was $14.13. Since
then, Isis Pharmaceuticals, Inc. has gained 264.90% as of 11/10/2015's recent price of $51.56.
If you would have followed this Morgan Joseph's recommendation on ISIS, you would have gained 264.89% of your investment in 2496 days.

Isis Pharmaceuticals, Inc. (Isis) is engaged in antisense technology, exploiting a drug discovery platform to create a pipeline of drugs. The Company operates in a two principal segments: Drug Discovery and Development and Regulus Therapeutics Inc. Within the Drug Discovery and Development segment, its drug discovery platform enables the Company to identify drugs, providing potential targets to treat a range of diseases. As of December 31, 2008, the Company has 19 drugs in development. Its partners are licensed to develop, with the Company?s support, 15 of these 19 drugs. The Company and Alnylam established Regulus Therapeutics Inc. as a company focused on the discovery, development and commercialization of microRNA therapeutics. In January 2009, the Company sold its subsidiary, Ibis Biosciences, Inc. to Abbott Molecular Inc. (AMI), a wholly owned subsidiary of Abbott Laboratories.

Morgan Joseph is committed to providing timely, objective and actionable investment advice on the companies and securities we follow. Our team of equity analysts covers a growing universe of stock issues across a broad range of industry sectors. As a middle market-focused firm, our approach is not to publish research on as many companies as possible within a number of industry sectors. Rather, our research analysts distinguish themselves by zeroing in on quality companies with growth prospects or which present special situations. These companies often lack a research following. This enables our analysts to provide insight to investors in companies that are not well understood nor fairly valued.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/9/2009 8:25 AM Buy
None
14.13 18.00
as of 12/31/2009
1 Week down  -17.15 %
1 Month down  -13.44 %
3 Months down  -36.37 %
1 YTD down  -34.39 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy